Ildong Holdings Co Ltd (000230) Fair Value & Analysis
Healthcare · KR · Market cap 68.5B KRW (≈ $48.0M) · ISIN KR7000230003
What is Ildong Holdings Co Ltd really worth?
Below-average quality, trading 61% below our fair value of 16,094 KRW.
Strengths
Risks
For context
Fair value as of: Aug 23, 2026
From 26 valuation models · updated 12 days ago
Share price +2.3% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The large discount to fair value meets weak quality (43/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (12,071 KRW). The market is more pessimistic than our downside scenario.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 23, 2026.
How to read this chart
60‑month range 5,686 KRW – 50,723 KRW · fair‑value band 12,071 KRW – 20,118 KRW · the 6,300 KRW price screens below the 16,094 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 23, 2026.
Analysis
Ildong Holdings Co Ltd (000230) currently trades at 6,300 KRW, while our model-based Fair Value estimate is 16,094 KRW, implying the stock looks roughly 60.9% undervalued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of 30,697 KRW per share, and 24 of the 26 models we run sit above the 6,300 KRW price. Bear case: the Asset-Based group reads lowest at 9,798 KRW, and 2 of the 26 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Ildong Holdings Co Ltd generated revenue of 599B KRW at a net margin of 2.9%. Revenue grew 5.5% year over year. It earns a return on equity of 10.1%. Net debt stands at 117B KRW. Fundamentals as of Aug 23, 2026
Our scenario range runs from 12,071 KRW (bear case) to 20,118 KRW (bull case); at 6,300 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 63% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at 155%, 000230 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: DCF Models (30,697 KRW) versus Dividend Discount (83.92 KRW). Highest evidence: FCF DCF (78).
Notify me when 000230 reaches fair value
Put 000230 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 42 · Market factors (momentum, volatility) 20
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Ildong Holdings Co., Ltd. develops, manufactures, and supplies pharmaceutical products in South Korea and internationally.
Full company description
Ildong Holdings Co., Ltd. develops, manufactures, and supplies pharmaceutical products in South Korea and internationally. It develops new drugs against resistant bacteria, malignant tumors, Alzheimer's disease, obesity, and ageing; and raw vitamins, probiotics, and antimicrobials, as well as offers Biovita, a lactobacillus product; and Aronamin, a multivitamin product. It is also involved in the research and manufacture of health foods and ingredients; and provides hyaluronic acid for use in drugs, medical devices, and cosmetics. In addition, the company distributes medical devices, quasi drugs, health supplements, food products, beverages, cosmetics, sanitary ware, and other healthcare products through online; and manufactures original and generic prescription drugs. Further, it offers probiotics; pharmaceutical SI consulting, system development and deployment, RFID and barcode systems, and other solutions; and engages in advertising business. The company was formerly known as Ildong Pharmaceutical Co., Ltd. and changed its name to Ildong Holdings Co., Ltd. in August 2016. Ildong Holdings Co., Ltd. was founded in 1941 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Ildong Holdings Co Ltd reported revenue of 591B KRW in FY2025 versus 592B KRW in FY2021, a compound −0.1%/yr. Reported net income was 10.9B KRW in FY2025.
Watch 000230: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 608 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare Ildong Holdings Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Ildong Holdings Co Ltd (000230) overvalued or undervalued?
What is the fair value of 000230?
What is the quality score of 000230?
What is the revenue of Ildong Holdings Co Ltd (000230)?
What is the net profit margin of 000230?
Does Ildong Holdings Co Ltd pay a dividend?
Watch Ildong Holdings Co Ltd in the live analysis
One click puts Ildong Holdings Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.